Tumor Profiling Market Size, Share and Outlook 2034
Tumor Profiling Market Growth, Size, Trends Analysis- By Technique, By Technology, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25313 | Pages: 1 - 230 | Formats*: |
| Category : Healthcare | |||
Tumor Profiling Market Introduction and Overview
According to SPER Market Research, the Global Tumor Profiling Market is estimated to reach USD 25.72 billion by 2034 with a CAGR 3.58%.
The report includes an in-depth analysis of the Global Tumor Profiling Market, including market size and trends, product mix, Applications, and supplier analysis. The global Tumor Profiling Market was valued at USD 18.09 billion in 2024 and is expected to grow at a CAGR of over 3.58% from 2025 to 2034. The growing prevalence of cancer and the increasing adoption of precision oncology, which customizes treatment based on each tumor’s genetic profile, are major drivers of market growth. Advances in technologies like next-generation sequencing are improving the efficiency and accuracy of tumor profiling, boosting its integration into oncology practices. Rising cancer incidence worldwide, driven by factors such as aging populations, unhealthy lifestyle choices, and environmental carcinogen exposure, is further fueling demand. Consequently, the need for effective cancer diagnosis and treatment is significantly supporting the tumor profiling market.
By Technique:
Genomics holds the largest share of the market, driven by its vital role in detecting genetic changes that fuel tumor growth and in guiding the creation of targeted therapies. The adoption of next-generation sequencing has greatly enhanced the precision and efficiency of genomic analysis, making it a cornerstone of precision oncology. Healthcare providers increasingly rely on genomic profiling to design personalized treatment strategies, while supportive regulatory approvals and active research continue to strengthen this segment. Meanwhile, epigenetics is anticipated to expand most rapidly, as studying DNA and histone modifications offers deeper insights into tumor biology and personalized cancer care.
By Technology:
Sequencing techniques lead the market, driven by their ability to deliver rapid and comprehensive genetic insights, with next-generation sequencing playing a transformative role in tumor profiling. These methods help detect mutations, gene fusions, and other abnormalities, supporting precision oncology and personalized treatment. Growing cancer incidence and rising demand for targeted therapies are fueling adoption, while advancements in efficiency, automation, and bioinformatics enhance accuracy and accessibility. Immunohistochemistry is projected to expand most rapidly, as it enables precise detection and localization of tumor markers, making it essential for cancer diagnosis and classification.
By Application:
Personalized cancer medicine leads the market, driven by its ability to design treatments tailored to a patient’s and tumor’s genetic profile, resulting in more precise and effective therapies. By focusing on specific mutations, this approach reduces harm to healthy cells, lowering side effects and improving outcomes. Adoption is rising with advances in sequencing and biomarker discovery, which strengthen tumor profiling accuracy. At the same time, research is expanding rapidly, supported by public and private funding that fosters innovation, explores tumor heterogeneity, identifies new targets, and advances precision oncology strategies.
Regional Insights:
North America leads the tumor profiling market, supported by a high cancer burden, strong investments in research, and rapid adoption of advanced technologies. Rising cancer prevalence has increased the need for accurate diagnostics and personalized therapies, while public-private partnerships and significant funding have advanced proteomics and genomics. The integration of next-generation sequencing and liquid biopsy into clinical practice has improved patient outcomes by enabling tailored treatments. Meanwhile, Asia Pacific is projected to grow most rapidly, driven by rising cancer cases, expanding precision medicine adoption, investments in healthcare infrastructure, and government-backed initiatives advancing early detection and targeted therapies.
Market Competitive Landscape:
The Tumor Profiling Market is highly consolidated. Some of the market key players are Bruker Spatial Biology, Inc., Exact Sciences Corporation, Foundation Medicine, Inc., GenomeDX, Guardant Health, Illumina Inc., NeoGenomics Laboratories, Oxford Gene Technology IP Limited, QIAGEN.
Recent Developments:
- In August 2024, Illumina secured FDA approval for its TruSight Oncology Comprehensive in vitro diagnostic test. This genomic profiling kit analyzes more than 500 genes and features pan-cancer companion diagnostic claims, allowing faster identification of patients suitable for targeted therapies.
- In 2022, QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit, designed to detect the C797S mutation and guide treatment decisions for non-small cell lung cancer (NSCLC). This molecular diagnostic test enhances precision medicine by providing comprehensive insights into EGFR mutation status, supporting targeted therapy selection.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Technique, By Technology, By Application |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Bruker Spatial Biology, Inc., Exact Sciences Corporation, Foundation Medicine, Inc., GenomeDX, Guardant Health, Illumina Inc., NeoGenomics Laboratories, Oxford Gene Technology IP Limited, QIAGEN. |
- Global Tumor Profiling Market Size (FY’2021-FY’2034)
- Overview of Global Tumor Profiling Market
- Segmentation of Global Tumor Profiling Market By Technique (Genomics, Proteomics, Metabolomics, Epigenetics)
- Segmentation of Global Tumor Profiling Market By Technology (Sequencing Techniques, In Situ Hybridization, Immunohistochemistry, qPCR, Microarray)
- Segmentation of Global Tumor Profiling Market By End-use (Pharmacy & Retail Clinics, Physician Office, Urgent Care Clinics, Non-practice Clinics)
- Statistical Snap of Global Tumor Profiling Market
- Expansion Analysis of Global Tumor Profiling Market
- Problems and Obstacles in Global Tumor Profiling Market
- Competitive Landscape in the Global Tumor Profiling Market
- Details on Current Investment in Global Tumor Profiling Market
- Competitive Analysis of Global Tumor Profiling Market
- Prominent Players in the Global Tumor Profiling Market
- SWOT Analysis of Global Tumor Profiling Market
- Global Tumor Profiling Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Tumor Profiling Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tumor Profiling Market
7. Global Tumor Profiling Market, By Technique, (USD Million) 2021-2034
- 7.1. Genomics
- 7.2. Proteomics
- 7.3. Metabolomics
- 7.4. Epigenetics
8. Global Tumor Profiling Market, By Technology, (USD Million) 2021-2034
- 8.1. Sequencing Techniques
- 8.2. In Situ Hybridization
- 8.3. Immunohistochemistry
- 8.4. qPCR
- 8.5. Microarray
9. Global Tumor Profiling Market, By Application, (USD Million) 2021-2034
- 9.1. Personalized Cancer Medicine
- 9.2. Oncological Diagnostics
- 9.3. Research
10.Global Tumor Profiling Market, (USD Million) 2021-2034
- 10.1.Global Tumor Profiling Market Size and Market Share
11. Global Tumor Profiling Market, By Region, 2021-2034 (USD Million)
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Bruker Spatial Biology, Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Exact Sciences Corporation
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Foundation Medicine, Inc.
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. GenomeDX
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Guardant Health
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Illumina Inc.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. NeoGenomics Laboratories
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Oxford Gene Technology IP Limited
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. QIAGEN
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Tumor Profiling Market grew in Market size from 2025. The Market is expected to reach USD 25.72 billion by 2034, at a CAGR of 3.58% during the forecast period.
Tumor Profiling Market is projected to reach USD 25.72 billion by 2034, growing at a CAGR of 3.58% during the forecast period.
Tumor Profiling Market CAGR of 3.58% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Tumor Profiling Market size is USD 25.72 billion from 2025 to 2034.
Tumor Profiling Market is covered By Technique, By Technology, By Application
North America is anticipated to have the highest Market share in the Tumor Profiling Market.
Bruker Spatial Biology, Inc., Exact Sciences Corporation, Foundation Medicine, Inc., GenomeDX, Guardant Health, Illumina Inc., NeoGenomics Laboratories, Oxford Gene Technology IP Limited, QIAGEN.
The report includes an in-depth analysis of the Tumor Profiling Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
